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OBJECTIVEdPregnancy in type 1 diabetes requires excellent glycemic control. Most preg-
nant type 1 diabetic women achieve normoglycemia; however, there is scarce data on their
postdelivery characteristics. We aimed to examine postpregnancy glycemic control and weight
changes in type 1 diabetes.
RESEARCH DESIGN AND METHODSdWe identified and followed (median 20
months) 254 women with singleton pregnancies receiving postdelivery medical care at a single
institution.
RESULTSdStudy subjects were 28.36 4.7 years of age (mean6 SD), with a diabetes duration
of 12.0 6 7.7 years. Mean A1C before conception was 6.9 6 1.4%, and preconception weight
and BMI were 64.46 10.0 kg and 23.96 3.3 kg/m2, respectively. Mean A1C decreased during
pregnancy, reaching 5.7 6 0.8% in the third trimester. We observed a mean weight gain of
14.46 6.5 kg during pregnancy. Within 6 months after delivery, A1C increased by 0.8% (P,
0.0001) compared with the last trimester, and body weight and BMI were 4.4 kg and 2.5 kg/m2
higher (P , 0.0001) compared with the preconception baseline. A1C further deteriorated by
0.8%until the end of follow-up. For women in the “pregnancy planning” program (n = 117), A1C
.12 months after delivery was worse compared with before conception (7.1 vs. 6.5%, P =
0.0018), whereas in women with unplanned pregnancies, it was similar to the pregestational
levels (7.3 vs.7.4%, P = 0.59). Weight and BMI in the entire study group did not return to
prepregnancy levels and were 2.5 kg (P = 0.0079) and 0.9 kg/m2 higher (P = 0.0058).
CONCLUSIONSdIn this clinical observation, type 1 diabetic women showed postpregnancy
deterioration in glycemic control and were unable to return to prepregnancy weight. Type 1
diabetic women seem to require special attention after delivery to meet therapeutic targets.
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The risk of maternal and fetal adverseoutcomes is greater in pregnanciescomplicated by type 1 diabetes than
in nondiabetic women (1). This is related
to the degree of hyperglycemia during
pregnancy (1,2). Optimized glycemic con-
trol improves the prognosis in these preg-
nancies, and most pregnant type 1 diabetic
women achieve normoglycemia (3–5).
Randomized trials and observational stud-
ies, including a report from our center,
demonstrated that both multiple daily
injections (MDIs) and continuous subcuta-
neous insulin infusion (CSII) are equally
effective and safe (4,5). However, there is
scarce data on glycemic control changes
after delivery.
Several factors potentially deteriorate
glycemic control in type 1 diabetic mothers
after delivery: less incentive to achieve good
metabolic control compared with during
pregnancy, duties associated with childcare,
and fear of hypoglycemic episodes dur-
ing childcare. Additionally, women have
different therapeutic goals and targets dur-
ing and after pregnancy (6). On the other
hand, extensive education programs during
pregnancy could help new mothers main-
tain improved glycemic control after deliv-
ery (7). Only one small observational study
exists for type 1 diabetes, showing that
after a substantial improvement during
pregnancy, glycemic control deteriorated,
reaching pregestational levels after delivery
(8). An urgent need exists for new, up-to-
date studies, as the therapeutic aims and
tools available 20 years ago have changed
dramatically.
Weight gain is another poorly investi-
gated clinical phenomenon in type 1 di-
abetic pregnancy. This problem should be
further explored as intensive insulin ther-
apy is associated with a large weight gain
(9).Weight increases graduallyduring adult
life, but for women, pregnancy can signifi-
cantly alter their tendency to gain weight.
Current literature demonstrates that in the
general population, excess weight gain dur-
ing pregnancy is related to a higher BMI
later in life (10). We have recently reported
that although modern insulin treatments
provide excellent glycemic control in preg-
nancies complicated by type 1 diabetes,
they also result in a substantial weight
gain, particularly in women on CSIIs,
where a 15-kg increase was observed (5).
In this study, we aimed to examine the
following: 1) postpregnancy glycemic con-
trol and weight changes in type 1 diabetic
women, and 2) potential modifying factors
such as early pregnancy planning, glycemic
control during pregnancy, and postdeliv-
ery diabetes treatment methods.
RESEARCH DESIGN AND
METHODSdThis study was perfor-
med at the Department of Metabolic
Diseases ( Jagiellonian University Medical
College), a university referral center for
diabetes care in southeastern Poland. All
pregnant women with preexisting type 1
diabetes were registered between 1999
and 2011 (5). In this study, we included
all patients whomet the following criteria:
1) clinical diagnosis of type 1 diabetes es-
tablished at least 1 year prior to concep-
tion, 2) medical care in the department
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initiated no later than in the first trimester
of gestation, and 3) complete follow-up in
the department until delivery and at least
one postpartum visit. We excluded pa-
tients with miscarriages (,24 weeks of
gestation). We initially identified 378 sin-
gleton pregnancies complicated by type 1
diabetes receiving medical care during
pregnancy. The number of registered sub-
jects had risen gradually from 26 in 1999;
the highest number, 42 subjects, was re-
corded in 2009. The final analysis in-
cluded 254 Caucasian patients with
available follow-up data after delivery.
As described earlier (5), women with
type 1 diabetes who were pregnant or plan-
ning to conceive received intensive diabetes
education, frequent outpatient visits, and
hospitalizations, if necessary, with the fol-
lowing therapeutic targets: 1) A1C ,6.1%,
2) fasting self-monitored blood glucose
within 60–90 mg/dL, and 3) subsequent
pre- and postprandial glucose self-
measurements within 60–120 mg/dL. Prior
to conception, 117 women (46%) started
intensive diabetesmanagement (“pregnancy
planning”). They were advised on contra-
ception methods until glycemic targets
were achieved. The other 137 (54%)
women entered the intensive diabetes man-
agement program in the first trimester.
Therefore, the terms “pregnancy planning,”
“planned,” and “unplanned” used in this pa-
per refer to the time of entry into our diabe-
tes program. Baseline characteristics, which
included microvascular complications,
were based on an examination during preg-
nancyplanning or during thefirst visit in the
first trimester. Retinopathy was diagnosed
ophthalmoscopically, and diagnosis of ne-
phropathy was based on the albumin excre-
tion rate, with values.30mg/24 h or urine
albumin-to-creatinine ratio.30 mg/g con-
sidered abnormal. The glomerular filtration
rate was calculated from serum creatinine
with the Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) formula.
All women received a thorough edu-
cation covering self-monitoring of blood
glucose (SMBG),glycemic targets,diet,phy-
sical activity, and self-adjustment of insulin
doses. Subjects treated with CSII received
additional instructions regarding pump
usage. All womenwere advised to perform
SMBG measurements with glucose meters
at least eight times daily (typically fasting,
before, and 1 h after main meals, at bed-
time, and between 2:00 and 4:00 A.M.).
Routine visits before and during pregnancy
were held every 4 weeks.
After delivery, patients were encour-
aged to have a follow-up in the clinic 1
month postpartum and then approxi-
mately every 3 months. During these visits,
glycemic control andweight were assessed.
Women were instructed to perform SMBG
at least six to seven times daily (fasting,
before main meals, 2 h postprandial, and
bedtime). Information was provided by the
physician on postdelivery glycemic goals
and diet. Additional sessions with a di-
etitian were scheduled if necessary.
Wedivided all postpregnancy follow-up
measurements into three groups: within 6
months of delivery (n = 131), 6–12 months
from delivery (n = 102), and after .12
months (n = 159). To examine the effect
of CSII treatment discontinuation, we also
obtained measurements taken during CSII
treatment after delivery, within 6 months
after CSII termination, and.6 months af-
ter CSII termination. The local bioethical
committee accepted this observational
study protocol.
A1C was analyzed using high-
performance liquid chromatography on
the Variant apparatus (Bio-Rad). The inter-
and intra-assay coefficient of variation
was ,2%. The device remained within
the system of international quality control
throughout the study period.
To examine temporal trends in A1C,
body weight, and BMI after pregnancy, the
repeated-measures linear model was used.
We used pregnancy planning, CSII treat-
ment during and after pregnancy, and their
interactions as covariates. We also exam-
ined the A1C profile for its impact on
weight changes. By minimizing the Akaike
information criterion, we selected the first-
order antedependence covariance structure
of longitudinal measurements. Model pa-
rameters were estimated with the restricted
maximum likelihood method using a
ridge-stabilized Newton-Raphson algo-
rithm in SAS 9.2 (Cary, NC) PROC
MIXED. P values ,0.05 were considered
significant.
RESULTSdStudy group baseline clini-
cal characteristics are presented in Table 1.
Patients reached excellent glycemic control
during pregnancy, withmean A1C 5.7% in
the third trimester. They were followed
for a median of 20 months (1st–3rd quar-
tile, 6–44 months). Almost half of the pa-
tients (46%) participated in a diabetes
management program forwomenplanning
pregnancy offered by the department. A
majority of the women (56%) were treated
with CSII during pregnancy, which was ei-
ther introduced before conception or in the
first trimester. Only 15% owned insulin
pumps and continued this treatment
through the follow-up period. The other
women temporarily obtained CSII devices
from the department and returned them
after a median of 2.4 months after delivery.
During the first 6 months after de-
livery, A1C increased by 0.8% (P ,
0.0001) from a mean of 5.7% in the third
trimester. After a subsequent 6 months,
A1C further deteriorated by 0.6% (P ,
0.0001). The last A1C recorded (.12
months from delivery) increased further
by 0.2% as compared with the prior mea-
surement (P = 0.055). Thus, during the
entire follow-up, A1C deteriorated by
1.6% (P , 0.0001). Postpregnancy A1C
was characterized by a larger dispersion,
with variance increasing almost four
times, compared with pregnancy values.
Women in the pregnancy planning
program (n = 117) had significantly lower
mean pregestational A1C (6.5 vs. 7.3%,
P , 0.0001). These women, either on a
CSII or MDI regimen, reached better
glycemic control in the third trimester
(5.6 vs. 5.8%, P = 0.011). However, after
delivery, there were no significant differ-
ences in A1C between the planning and
not planning women within 6 months of
delivery (6.3 vs. 6.6%, P = 0.09), 6–12
months later (6.9 vs. 7.1%, P = 0.59), and
after .12 months after delivery (7.1 vs.
7.4%, P = 0.32) (Fig. 1). At the end of
follow-up, A1C returned to prepregnancy
levels in women with unplanned pregnan-
cies. However, in the pregnancy planning
group, A1C deteriorated to levels signifi-
cantly higher than before conception (P =
0.0018).
In women treated with CSII during
pregnancy and who discontinued this
treatment after delivery, we observed a
significant increase in A1C while they still
received CSII treatment (5.6–6.5%, P ,
0.0001). We subsequently observed a fur-
ther deterioration to mean A1C 7.1%
within 6 months after switching to the
MDI regimen in comparison with 6.5%
on CSII (P = 0.018). More than 6 months
after CSII discontinuation, A1C was 7.2%.
Only women who continued CSII with
their own pumps (n = 37) reached substan-
tially better A1C levels at the end of follow-
up (6.7 vs. 7.3%), although this difference
had only borderline significance (P =
0.059). This CSII subgroup included both
planning and not planning subjects (26
and 11 subjects, respectively).
During pregnancy, mean bodyweight
increased by 14.4 kg, reaching 78.8 kg
(P , 0.0001). Within 6 months after de-
livery, mean patient weight remained el-
evated (68.8 kg) compared with before
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pregnancy, by 4.4 kg (P, 0.0001), which
corresponded to a mean BMI increase
from 23.9 to 25.5 kg/m2 (P , 0.0001)
(Fig. 1). A decrease was observed during
follow-up, as .12 months after delivery,
weight dropped by 1.9 kg and BMI by 0.7
kg/m2 (P = 0.031 and P = 0.020, respec-
tively), reaching 66.9 kg (mean BMI 24.8
kg/m2) (Fig. 1). Overall, at the end of
follow-up, both body weight and BMI
were greater than before pregnancy,
by 2.5 kg and 0.9 kg/m2, respectively
(P = 0.0079 and P = 0.0058). A1C did
not appear to have a significant effect on
weight variation. No differences were ob-
served between temporal trends of weight
and BMI during follow-up, comparing
planning and not planning cohorts, or be-
tween CSII- and MDI-treated women.
CONCLUSIONSdIn this large clinical
observation, type 1 diabetic women who
achieved excellent glycemic control during
pregnancy were found to experience sub-
stantial postdelivery glycemic control
deterioration. This trend was observed
not only in type 1 diabetic women with
unplanned pregnancies but also in subjects
with planned pregnancies who had better
diabetes control during pregnancy. Addi-
tionally, study participants weighed on
average 2.4 kg more at the end of the study
than before pregnancy.
The problem of glycemic control in
type 1 diabetic women during pregnancy
and its impact on maternal and fetal out-
comes has attracted a lot of attention over
the recent years (1). Therapeutic aims spe-
cific for pregnancy complicated by diabetes
are included into the major clinical guide-
lines (6). Interestingly, the problem of met-
abolic control after delivery remains almost
unexplored. The current study is just the
second investigating this problem, with the
earlier report involving 30 type 1 diabetic
patients examined between 1992 and 1994
(8). The conclusions were similar to ours;
most type 1 diabetic patients had substan-
tially improved glucose levels during preg-
nancy, and glucose control deterioration
was observed after delivery. The current
study is substantially larger than the U.K.
cohort andmajorly differs in the A1C levels
achieved in the examined groups. Mean
preconception A1C levels in the U.K. and
our cohorts were 9.9 and 6.9%, respec-
tively, 7.0 and 5.7% in the third trimester,
and the last follow-up values were 9.7 and
7.3%, respectively. These data are likely the
result of increasingly strict contemporary
therapeutic aims and new tools such as in-
sulin analogs, personal pumps, and moni-
toring devices. However, in spite of much
better glycemic control in our cohort, A1C
values after pregnancy were higher than
recommended for type 1 diabetes (11).
The guidelines for glycemic control, ex-
pressed as both glycosylated hemoglobin
and SMBG values in type 1 diabetes in
the general population, have been less strict
than the targets for pregnant women. For
example, the current recommended A1C
goal in Poland has been 6.5% since 2006
(12). We previously mentioned several rea-
sons forpostdeliverydeteriorationof glycemic
control. An underestimated cause may be
the relaxed stringency of diabetes manage-
ment. For example, after the delivery, the
visits were less frequent and the minimal
recommended SMBG measurements
number was slightly lower. Although the
postulate of maintaining pregnancy-level
glycemic control after delivery is unrealis-
tic, attention should be paid to reach gen-
eral type 1 diabetes goals.
Our study is the first that describes
weight changes after delivery in a group of
Table 1dPatient characteristics
Total group Pregnancy planning Not planning
P value
(planning vs. not planning)
Number of subjects (n) 254 (100) 117 (46) 137 (54) d
Age (years) 28.3 6 4.7 28.8 6 4.2 27.9 6 5.1
0.15
28.0 (25.0–31.3) 28.2 (26.0–31.6) 27.5 (24.3–30.7)
Diabetes duration (years) 12.0 6 7.7 13.3 6 8.2 11.0 6 7.1
0.018
12.0 (5.0–18.0) 14.0 (6.0–19.0) 11.0 (5.0–17.0)
Preconception BMI (kg/m2) 23.9 6 3.3 23.7 6 3.2 24.1 6 3.4
0.34
23.3 (21.8–25.6) 23.2 (21.7–25.1) 23.5 (21.9–25.7)
Preconception body weight (kg) 64.4 6 10.0 64.0 6 10.3 64.8 6 9.8
0.55
64.0 (58.0–70.0) 63.0 (58.0–68.0) 64.0 (59.0–70.0)
Weight gain during pregnancy (kg) 14.4 6 6.5 14.2 6 7.0 14.6 6 6.2
0.66
14.0 (11.0–18.0) 14.0 (10.0–19.0) 15.0 (11.0–18.0)
Gestational age (weeks) 38.3 6 2.5 38.2 6 2.4 38.4 6 2.5
0.49
39.0 (37.0–40.0) 39.0 (37.0–39.0) 39.0 (37.0–40.0)
A1C before pregnancy (%) 6.9 6 1.4 6.5 6 1.2 7.3 6 1.5
,0.0001
6.7 (6.1–7.5) 6.6 (6.0–7.1) 7.0 (6.3–8.1)
CSII treatment during pregnancy (n) 143 (56.3) 72 (61.5) 71 (51.8) 0.12
CSII until end of follow-up (n) 37 (14.6) 26 (22.2) 11 (8.0) 0.0014
Cesarean section (n) 175 (68.9) 87 (74.4) 88 (64.2) 0.082
Retinopathy of any degree (n) 81 (31.9) 38 (32.5) 43 (31.4) 0.85
Proliferative retinopathy (n) 12 (4.7) 5 (4.2) 7 (5.1) 1.0
Abnormal urinary albumin (n) 7 (2.8) 3 (2.6) 4 (2.9) 1.0
GFR (mL/min/1.73 m2) 125 6 14 123 6 9 127 6 17
0.072
125 (119–133) 122 (118–130) 128 (122–135)
CKD stage 3 or higher 1 (0.4) 0 (0.0) 1 (0.7) 1.0
Data are mean6 SD, median (1st–3rd quartile), or n (%). Planning vs. not planning compared with Student t test, x2 test, or Fisher exact test, where applicable. GFR,
glomerular filtration rate.
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type 1 diabetic women. The patients in our
study experienced a large weight increase
during pregnancy. A weight gain of 2.5 kg
measured after amedian of 20months after
delivery as compared with the prepreg-
nancy baseline seems to be similar to the
general female population (10). One may
postulate that less weight gain during preg-
nancy than observed in this cohort (14.4
kg) would likely make it easier to return to
the preconception baseline. This may be
particularly true for the CSII method, as
in our earlier report, it wasmore predispos-
ing to weight gain than the MDI model in
type 1 diabetes–complicated pregnancy
(15 vs. 13 kg, respectively) (5). We also
recently reported a cohort of type 2 diabetic
women who gained ,10 kg during preg-
nancy, likely due to the special attention
paid to caloric restriction in an education
program (11).
The current study is characterized by
shortcomings related to nonrandom factors
possibly influencing the results. For exam-
ple,.100 women did not show up in the
clinic after the delivery. Medical care of
pregnant type 1 diabetic women in Lesser
Poland (the administrative region of which
Krakow is the capital) is centralized and
patients are encouraged to register at the
Department of Metabolic Diseases, op-
timally during pregnancy planning or,
at the latest, in early pregnancy. It is
likely that most of the missed postpar-
tum follow-up appointments resulted
from the women returning to their local
diabetes centers, which is particularly un-
derstandable in the light of duties related
to childcare. However, one cannot entirely
exclude that they were less motivated and,
thus, characterized by poor glycemic con-
trol. Nevertheless, this possibility seems to
be very unlikely, as during pregnancy,
women who dropped from observation
had similar glycemic control as the rest
of the study group (data not shown). Ad-
ditionally, although women who contin-
ued CSII may seem to be less prone to
postpregnancy glycemic control deterio-
ration, the possibility that they were better
educated about diabetes therapy andmore
motivated should be considered. In
women who discontinued CSII, deteriora-
tion of glycemia was observed when still
on CSII, which paralleled the A1C
changes seen in MDI-treated women.
In conclusion, type 1 diabetic women
showed postpregnancy deterioration in
glycemic control. They were also unable
to return to their prepregnancy weight.
Type 1 diabetic women seem to require
special medical attention after delivery to
maintain their diabetes control within
therapeutic targets.
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